Data as of 3:59pm ET
| -2.12 / -2.55%|
GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Sativex Commercial, Sativex Research and Development and Pipeline Research and Development. The Sativex Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The current focus for this segment is the Phase III clinical development programme of Sativex for use in treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Group's proprietary cannabinoid technology platform and partnerships with international scientists. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.
|Justin D. Gover||Chief Executive Officer, MD & Executive Director|
|Christopher John Tovey||Chief Operating Officer & Executive Director|
|Adam David George||CFO, Secretary & Executive Director|
|Richard Potts||Director-Clinical Operations|
|Colin Stott||Director-Research & Development Operations|